Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT‐1014‐6470, a Novel Oral Complement Factor 5a Receptor 1 Antagonist
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1184
Abstract: The aim of this study was to examine the safety and the effect of severe renal impairment (RI) on the pharmacokinetics of ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 antagonist. A phase 1… read more here.
Keywords: safety; effect severe; 1014 6470; act 1014 ... See more keywords